Sumitomo Pharma
As of the edition of 20 October 2026, Sumitomo Pharma runs 42 drugs, 9 of them marketed; it is on route A at 16 targets and on route B at 6 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 8 company names in this family.
- Sumitovant Biopharma, Inc.: acquired in 2019; successor SUMITOMO PHARMA CO., LTD.
- Myovant Sciences GmbH: acquired in 2023; successor Sumitovant Biopharma, Inc.
- Sunovion Pharmaceuticals Inc: renamed in 2023
Drugs by status
| Status | Count |
|---|---|
| Marketed | 9 |
| Active | 7 |
| Went quiet | 10 |
| Stopped | 11 |
| Status not established | 5 |
| Total | 42 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Glycopyrronium | none listed | 10 |
| Lurasidone | none listed | 4 |
| Eslicarbazepine acetate | Ended 2026 (patent) | 2 |
| Relugolix | Ends 2033 (patent) | 3 |
| Eszopiclone | none listed | 0 |
| Apomorphine | none listed | 1 |
| Arformoterol | none listed | 0 |
| Vibegron | Ends 2034 (patent) | 2 |
| Eslicarbazepine | none listed | 2 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 16 targets, route B at 6 targets.
All 22 rows on route A or B
In the product22 company-target rows on route A or B; 19 are not shown here, and no score is.
See all 22 targets where Sumitomo Pharma needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Mental health: 61 trials led
- Cancer: 53 trials led
- Urinary and reproductive: 20 trials led